Original Research Article
Year: 2020 | Month: December | Volume: 7 | Issue: 12 | Pages: 19-22
Apremilast, A Recent Advance in Systemic Treatment of Psoriasis (25 Cases)
Richa Ginodiya1, Deval Vora2, Vijay Soyal3, Jinali Makwana3
1Third Year Resident, Skin and VD, MP Shah Medical College, Jamnagar
2Professor and Head, Skin and VD, MP Shah Medical College, Jamnagar
3Second Year Resident, Skin and VD, MP Shah Medical College, Jamnagar
Corresponding Author: Richa Ginodiya
ABSTRACT
Introduction: Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4) has been licensed by the US Food & Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (Sep 23, 2014).
Aims & objectives: Aim of the study is to evaluate the utility of Apremilast in the treatment of psoriatic patients, despite prior therapy with conventional disease modifying drugs.
Materials & methods: Total 25 patients were included in our study. Tablet Apremilast 30mg in twice daily dosing was given to all patients. All routine investigations are done. The effect of administration of drug was recorded by PASI score.
Result: In all 25 patients, Tablet Apremilast 30mg twice daily given. At the end of 16 weeks, significantly more patients taking Apremilast achieved 75% reduction PASI -75 in 32% of patients, PASI-50 in 56% of patients and 12% patients left the study. No significant adverse events emerged with continued Apremilast exposure.
Conclusion: Orally administered Apremilast is an effective, generally well tolerated & convenient option for the treatment of psoriasis.
Keywords: Apremilast, Psoriasis, PASI.
[PDF Full Text]